8-K: Atara Biotherapeutics Announces Q4 and Full Year 2024 Financial Results, Pauses CAR-T Programs

Atara Biotherapeutics reports Q4 and full year 2024 financial results, pauses CAR-T programs, and focuses on EBVALLO BLA resubmission.

Summary

• Atara Biotherapeutics announced its fourth quarter and full year 2024 financial results, along with operational progress.
• The company is focusing on the future financial value of EBVALLO and is working with partners and the FDA to lift the clinical hold and support the BLA resubmission in the U.S.
• Atara has paused its ATA3219 and ATA3431 CAR-T programs and implemented a workforce reduction of approximately 50% to preserve resources.
• A strategic review by a financial advisor is ongoing to explore potential strategic options for the company.
• In January 2025, the FDA issued a Complete Response Letter (CRL) for the EBVALLO BLA, citing issues at a third-party manufacturing facility.
• Atara anticipates providing a regulatory update in the second quarter of 2025 regarding the EBVALLO BLA resubmission.
• The company has entered into a non-binding term sheet with Redmile Group for up to $15 million in funding through an equity line of credit.
• Cash, cash equivalents, and short-term investments totaled $42.5 million as of December 31, 2024, compared to $51.7 million as of December 31, 2023.
• Net loss for the fourth quarter of 2024 was $12.7 million, or $1.19 per share, and $85.4 million, or $11.41 per share, for the full year.

Sentiment

Score: 4

Explanation: The sentiment is slightly negative due to the FDA rejection, program pauses, and workforce reduction, although the company is taking steps to address the issues and secure funding.

Positives

• Atara is actively working with its partner and the FDA to address the issues raised in the Complete Response Letter for EBVALLO.
• The company has a second third-party manufacturer, FUJIFILM Diosynth Biotechnologies (FDB), approved by the EMA to ensure a reliable supply of EBVALLO for the U.S. market.
• Atara remains eligible for significant milestone payments and royalties from Pierre Fabre upon FDA approval of the EBVALLO BLA.
• The company has secured a potential $15 million equity line of credit to fund ongoing activities required to achieve BLA approval.
• The first patient in the Phase I dose escalation study of ATA3219 successfully completed dosing and the administration of two infusions of ATA3219 was well tolerated with no evidence of graft versus host disease or other safety events.

Negatives

• The FDA issued a Complete Response Letter (CRL) for the EBVALLO BLA due to issues at a third-party manufacturing facility.
• Atara received a clinical hold notice from the FDA on EBVALLO studies linked to the CRL.
• The company has paused its ATA3219 and ATA3431 CAR-T programs and discontinued all CAR-T operations.
• Atara implemented a workforce reduction of approximately 50%.
• The company reported a net loss of $12.7 million for the fourth quarter of 2024 and $85.4 million for the full year.

Risks

• The company faces risks related to the timing of the transfer of all operational activities related to EBVALLO to Pierre Fabre, which could create additional expenses and cash needs.
• There are uncertainties related to the ongoing discussions with Pierre Fabre, which are expected to lead to a reduction in the amount of certain future potential regulatory and commercial milestone payments from Pierre Fabre.
• The company faces risks and uncertainties associated with the costly and time-consuming pharmaceutical product development process and the uncertainty of clinical success.
• There are risks related to FDA feedback and the ability of Atara and its third-party manufacturer to address issues identified in the CRL.
• The company's ability to access capital and the sufficiency of its cash resources are uncertain.

Future Outlook

Atara is focused on addressing the issues at a third-party manufacturing facility, lifting the clinical hold, and resubmitting the EBVALLO BLA. The company is also exploring strategic alternatives and transitioning EBVALLO operational activities to Pierre Fabre.

Management Comments

• Cokey Nguyen, President and Chief Executive Officer of Atara, stated that Atara continues to productively engage with its partner Pierre Fabre Laboratories and the FDA to help the third-party manufacturer adequately address the GMP compliance issues as they continue to work toward an expeditious path to release the clinical hold and resubmit the EBVALLO BLA.
• Dr. Nguyen also conveyed gratitude to the patients, investigators, and collaborators for their participation in the CAR-T development efforts and thanked the Atara team members and stockholders for their commitment to the Company.

Industry Context

The announcement reflects the challenges and risks inherent in the biopharmaceutical industry, particularly in manufacturing and regulatory approvals. The pause in CAR-T programs highlights the competitive landscape and the need for companies to prioritize resources on their most promising assets. The strategic review suggests that Atara is considering various options to maximize shareholder value in a challenging environment.

Comparison to Industry Standards

• The FDA's Complete Response Letter (CRL) due to manufacturing issues is not uncommon in the biopharmaceutical industry; companies like Bristol Myers Squibb and Novartis have faced similar setbacks.
• The workforce reduction of 50% is a significant restructuring, potentially larger than similar actions taken by companies like Biogen and Sanofi in response to pipeline setbacks or strategic shifts.
• The exploration of strategic alternatives, including a potential acquisition or merger, is a common response for companies facing financial challenges or seeking to accelerate growth, as seen with Alexion Pharmaceuticals' acquisition by AstraZeneca.
• The reliance on third-party manufacturers introduces risks that are well-recognized in the industry, and companies often mitigate this risk by having multiple suppliers, as Atara is doing with FUJIFILM Diosynth Biotechnologies (FDB).

Stakeholder Impact

• Shareholders will be impacted by the strategic shift, potential dilution from the equity line of credit, and the outcome of the strategic review.
• Employees have been impacted by the workforce reduction.
• Patients may experience delays in access to EBVALLO.
• Suppliers and collaborators may be affected by the pause in CAR-T programs.

Next Steps

• Atara will work with its partner and the FDA to address the issues raised in the Complete Response Letter for EBVALLO.
• The company will support the third-party manufacturer in addressing the FDA's requests to lift the clinical hold and support BLA resubmission.
• Atara anticipates providing a regulatory update in the second quarter of 2025 regarding the EBVALLO BLA resubmission.
• The company will continue its strategic review process to explore potential strategic options.
• Atara will continue discussions with Pierre Fabre on accelerating the transfer of all operational activities related to EBVALLO.

Key Dates

Keywords

EBVALLO, Atara Biotherapeutics, BLA, CAR-T, FDA, Financial Results, Clinical Hold, Pierre Fabre, Strategic Review, Workforce Reduction, Redmile Group, Equity Line of Credit, PTLD, ATA3219, ATA3431